SAN ANTONIO (EGMN) - An all-oral combination chemotherapy regimen of vinorelbine and capecitabine makes for an effective, extremely convenient, and relatively comfortable first-line treatment in HER2-negative metastatic breast cancer, an international phase II clinical trial has shown.Adherence to this infusion-free regimen was strikingly good. The planned dose escalation of oral vinorelbine (Navelbine) from 60 mg/m² in the first cycle to 80 mg/m² thereafter occurred in 90% of patients. The median...